GOSS

Gossamer Bio, Inc.

Healthcare
Biotechnology
$66M market cap

Forecast run · Sep 14, 2026Upside rank 18 of 3,136

Model Signal

ForecastQ Daily Probabilities

88.8%

20.6%

77.3%

Analyst Consensus

Recommendation2.53/5 Hold

Last price$10.73

Price target$3.47

Implied move-67.7%

Analysts17

ForecastQ Portfolios

GOSS is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.